3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Completed
11
Terminated
2
Withdrawn
1
Unknown
1
Suspended
1
Sponsor Class
OTHER_GOV
1
Study Type
Interventional
1
Sponsor
Cancer Type
Head & Neck
1
Breast
1
Conditions
Pain
3
Pain, Postoperative
2
Neoplasms
2
Head and Neck Neoplasms
2
Wounds and Injuries
1
Supratentorial Neoplasms
1
Sigmoidal Tumour
1
Rectal Neoplasms
1
Pleural Effusion, Malignant
1
Parkinson Disease 4, Autosomal Dominant Lewy Body
1
Pain, Intractable
1
Neoplasm Metastasis
1
Nasopharyngeal Carcinoma
1
Nalbuphine Allergy
1
Immune System Suppression
1
Ileus
1
Diverticulosis, Colonic
1
Diverticulitis, Colonic
1
Constipation
1
Colonic Neoplasms
1
Chronic Pain
1
Cancer Pain
1
Breast Neoplasms
1
Breast Cancer Patients Undergoing Mastectomy With Immediate Reconstruction
1
Agnosia
1
Interventions
Pharmaceutical Services
2
Lidocaine
2
Ethanol
2
Acetaminophen
2
Venlafaxine Hydrochloride
1
Ropivacaine
1
Radiofrequency Ablation
1
Pregabalin
1
Oxycodone
1
Myofascial Release Therapy
1
Morphine
1
Methadone
1
Memantine
1
Ketamine
1
Hospitals
1
Gels
1
Dronabinol
1
Cholecalciferol
1
Calcium Dobesilate
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Unknown
×
Cancer Pain
×
Morphine
×
Clear all
NCT05800834
2023-09-28
MorphineGEL
Instituto Nacional de Cancer, Brazil
Phase 2
Unknown
106 enrolled